Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
First-in-Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN-3143, a Novel Inhibitor of Mono-Adenosine Diphosphate Ribosyltransferase-PARP14.
Journal: Clinical pharmacology in drug development
Published: January 08, 2024
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Journal: Cancer research communications
Published: February 23, 2022
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Journal: Investigational new drugs
Published: November 19, 2020
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 17, 2016
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 25, 2016
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 05, 2016
Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Journal: Oncotarget
Published: June 29, 2015
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 19, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026